Skip to main content
Harm Reduction· Explainer

The Alcohol Medicine That Pays for Itself Has Been Sitting on the Shelf Since 1994

A new JAMA Network Open model finds that treating drinking before the liver scars saves money and life, even if people drink again. Fewer than 2% of people with an alcohol use disorder get a medication.

ByThe Rize NewsroomNovember 19, 20266 min readAlcohol

The woman KFF Health News called Dede had done everything people are told to do about drinking. She went to hundreds of Alcoholics Anonymous meetings. She went to rehab twice, once at a place that cost her $30,000 out of pocket. She still drank. “The self-loathing was the worst thing about it,” she told the reporter in 2016. “I hated myself as an alcoholic, but I could not stop.” Then, in a counseling program at the University of North Carolina, someone mentioned a pill called naltrexone. She sat in a doctor’s office until he could see her. With the medicine and one-on-one counseling, she said, she hadn’t had more than two sips of wine since.

Nobody had told her about it, in all those years and all those rooms. A paper published Wednesday suggests that silence is still costing people their livers.

The cheapest liver treatment in America is a 30-year-old pill that treats the drinking, and we keep waiting until the liver is gone to offer it.

What the new model found, and what it can’t prove

Researchers at Columbia University Irving Medical Center, led by Annabel Gerber with senior author Chin Hur, built a computer model of 45-year-olds with an alcohol use disorder and stage 3 liver fibrosis. In plain terms, fibrosis is scar tissue building up in the liver; stage 3 means it is heavy but hasn’t yet hardened into cirrhosis, the point where the liver starts to fail. They followed the simulated patients for life and compared two paths: no treatment, or 16 weeks of naltrexone with a doctor checking in, plus a year of structured counseling. The results, published Nov. 18 in JAMA Network Open, came out on the side health economists almost never see. Treatment was cheaper and better at the same time. Lifetime liver-related costs were $78,673 with treatment against $79,799 without. Treated patients gained 0.67 “quality-adjusted life years,” a yardstick where a year in full health counts as one, so call it roughly eight months of good life. Liver deaths fell from 61% to 58% of the cohort, and progression to failing cirrhosis fell from 66% to 62%.

Those percentage-point gains are modest, and you should know why before you repeat them. This is a model, not a trial: nobody was randomized, and the outcomes depend on assumptions about how many people take the medicine and how many drink again. The authors say so. They also didn’t model the liver healing itself after people cut back, which they note probably understates the benefit. The finding that matters most is in the stress tests. Treatment stayed the better choice whether the simulated relapse rate was 0% or 100%, with any adherence above zero, and at treatment costs up to $5,000. That is the economics telling you something clinicians resist: you do not have to quit perfectly for treating the drinking to pay off.

The stakes are getting bigger, not smaller. A JAMA review published in July reports U.S. deaths from alcohol-related liver disease rose from 6.7 to 12.5 per 100,000 people between 1999 and 2022, and that among people with cirrhosis, stopping drinking was associated with less than half the risk of dying from liver disease over three years. Alcohol-induced deaths overall fell 4% in 2024, according to Trust for America’s Health. One good year doesn’t undo two decades of climbing.

How a pill helps with drinking, in plain words

Alcohol makes your brain release its own feel-good chemicals, the same family of chemicals opioid drugs imitate. That rush is part of why the second drink pulls harder than the first. Naltrexone sits in the receptors those chemicals use and blocks them, so drinking delivers less of the reward. People describe it less as a wall and more as the volume getting turned down. James Garbutt, the University of North Carolina psychiatrist who treated Dede, told KFF that “the effect of reducing heavy drinking is the most prominent effect of naltrexone.” It is a harm-reduction drug wearing a treatment label. Fewer heavy days means less damage to a liver that is already scarring, which is exactly the person the Columbia model describes.

Naltrexone sits in the receptors those chemicals use and blocks them, so drinking delivers less of the reward.

The limits are real, and they matter for your safety. Naltrexone blocks opioids too. If you take any opioid, whether pain pills, heroin, fentanyl, methadone or buprenorphine, taking naltrexone can throw you into sudden withdrawal, and it can make your tolerance drop so a later opioid dose hits harder. MedlinePlus lists the warnings and the liver monitoring a prescriber should do. It is not a controlled substance, and any licensed prescriber can write it. Whether your plan covers counseling alongside it, and how fast you can get a visit, is the other gate, and as today’s lead story on insurer ghost networks shows, a listed provider is not the same as an appointment.

If you have been told your liver enzymes are high, or a scan showed fat or scarring, and nobody mentioned a medicine for the drinking itself, you are the person this study is about. You can ask for it by name. You don’t have to promise abstinence first, and a doctor who makes that the price of the prescription is working from a rulebook the evidence left behind.

Thirty years of a working drug nobody sold

We have watched a cheap, unglamorous medicine sit unused while people died of the thing it treats, and we know how that happens. The FDA approved naltrexone for alcohol in 1994. The manufacturer had about three years of market exclusivity, and KFF reported it dropped its marketing push in 1997. “Three years is not a very long time to make a market where there really isn’t much of a market,” Penn’s Henry Kranzler said. The early label even told doctors patients should be completely sober before starting, which turned a drink-less drug into a reward for people who had already quit. Thirty years after approval, Medical Economics noted it remains underused relative to the evidence. Generic drugs don’t have sales reps. Nobody profits from telling your doctor about them.

The Columbia paper puts the scale in one line: fewer than 2% of people with an alcohol use disorder receive a medication for it. Compare that with how medicine treats the liver itself. Hepatologists, the liver specialists, monitor enzymes, order scans and track scarring stage by stage. The drinking that causes all of it often goes untreated in the same visit. Earlier this week we covered the VA’s new trial of semaglutide for drinking, and there is real excitement about the new drugs. The irony is that we already have one that works, costs little and has three decades of safety data, and we don’t use it.

For clinicians, the move this week is small and specific. Put a medication-for-drinking question into every visit where alcohol-related liver injury is on the chart, whether that’s elevated enzymes, fatty liver with heavy drinking, or any fibrosis stage, and document whether naltrexone (or acamprosate, for patients who can’t take it) was offered. Check for opioid use first. Pair the prescription with counseling or a referral that actually has an open slot, and set the goal as fewer heavy-drinking days, not a pledge.

Next Wednesday is the night before Thanksgiving, a night plenty of people who drink, and plenty in recovery, see coming from a long way off. If you are bracing for it, our alcohol coverage and harm-reduction reporting are there, and so is this: a medicine exists that makes the pull weaker, and you are allowed to ask for it before you’ve proven you can stop. Dede waited in an office until a doctor would see her. You shouldn’t have to wait that long. You also shouldn’t have to know the name already. Now you do.

Filed Under

harm-reductiontreatmentbiologyAlcoholMAT — NaltrexonePeer-Reviewed ResearchThe Treatment GapRelapse Prevention

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section